Nezone Medicines Profile
Key Indicators
- Authorised Capital ₹ 1.50 Cr
as on 29-05-2024
- Paid Up Capital ₹ 1.48 Cr
as on 29-05-2024
- Company Age 22 Year, 8 Months
- Last Filing with ROC 31 Mar 2023
- Satisfied Charges ₹ 1.55 Cr
as on 29-05-2024
About Nezone Medicines
The Company is engaged in the Chemicals Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.50 Cr and a paid-up capital of Rs 1.48 Cr.
The company has closed loans amounting to ₹1.55 Cr, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Hemo Saikia, Bandana Saikia, and Debabrata Saikia serve as directors at the Company.
- CIN/LLPIN
U24232AS2002PTC006795
- Company No.
006795
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
22 Apr 2002
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Shillong
Industry
Company Details
- Location
Kamrup, Assam, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Nezone Medicines?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Hemo Saikia  | Whole-Time Director | 01-Mar-2013 | Current |
| Bandana Saikia | Whole-Time Director | 29-Nov-2002 | Current |
| Debabrata Saikia | Whole-Time Director | 22-Apr-2002 | Current |
Financial Performance of Nezone Medicines.
Nezone Medicines Private Limited, for the financial year ended 2017, experienced no change in revenue, with a 0% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth witnessed no change by increase of 0%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets | |||||||
| Profit or Loss | |||||||
| Net Worth | |||||||
| EBITDA |
What is the Ownership and Shareholding Structure of Nezone Medicines?
In 2017, Nezone Medicines had a promoter holding of 62.67% and a public holding of 37.33%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Eastern Press And Publications LlpActive 7 years 3 monthsHemo Saikia and Debabrata Saikia are mutual person
- Pioneer Cryogenic Industries LlpActive 5 years 3 months
Bandana Saikia and Debabrata Saikia are mutual person
- Luit Real Estates Pvt LtdActive 27 years 3 months
Bandana Saikia and Debabrata Saikia are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
United Bank Of India Creation Date: 28 Feb 2006 | ₹1.25 Cr | Satisfied |
Canara Bank Creation Date: 29 May 2004 | ₹1.50 M | Satisfied |
Canara Bank Creation Date: 29 May 2004 | ₹1.50 M | Satisfied |
How Many Employees Work at Nezone Medicines?
Unlock and access historical data on people associated with Nezone Medicines, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Nezone Medicines, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Nezone Medicines's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
